Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | HRAS G12C |
| Therapy | Sotorasib |
| Indication/Tumor Type | head and neck carcinoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| HRAS G12C | head and neck carcinoma | no benefit | Sotorasib | Preclinical - Cell culture | Actionable | In a preclinical study, Lumakras (sotorasib) treatment resulted in decreased Erk1/2 phosphorylation at high concentrations, but did not inhibit proliferation in a head and neck carcinoma cell line harboring HRAS G12C in culture (PMID: 41340466). | 41340466 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41340466) | Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. | Full reference... |